Miltenyi, 130-113-321, CD141 (BDCA-3) Antibody, anti-human, Vio® Bright FITC

Overview
Clone AD5-14H12 recognizes the human CD141 (BDCA-3) antigen which is expressed at high levels on a minor subpopulation of human myeloid dendritic cells (about 0.02% of blood leukocytes). CD141 (BDCA‑3)high blood dendritic cells are CD11cdim, CD123–, CD4+, Lin–, CD45RO+, CD2–, and CD16–. They express myeloid lineage markers, such as CD13 and CD33, and have a monocytoid morphology. Unlike CD1c (BDCA-1)+ blood dendritic cells, CD141 (BDCA-3)high blood dendritic cells lack expression of CD2 and Fc receptors such as CD32, CD64, or FcεRI. CD141 (BDCA-3) is also present at very low levels on CD14+ monocytes, granulocytes, CD303 (BDCA‑2)+ CD304 (BDCA-4/Neuropilin-1)+ plasmacytoid and CD1c (BDCA-1)+ myeloid dendritic cells. CD141 (BDCA‑3)high CD1c (BDCA-1)– myeloid dendritic cells have been designated type-2 myeloid dendritic cells (MDC2s). CD141 is also known as thrombomodulin; thrombomodulin mediates co-agglutination by interaction with thrombin and protein C, though nothing is known about its function on MDC2s.